Literature DB >> 19172694

The art of measuring gastrin in plasma: a dwindling diagnostic discipline?

Jens F Rehfeld1.   

Abstract

The gastrointestinal hormone gastrin is measured in plasma in physiological, pathophysiological and diagnostic investigations. In the diagnosis of hypergastrinaemic diseases such as gastrinomas and gastric achlorhydria, measurement of gastrin concentrations in circulation is crucial. Gastrin circulates, however, not as a single peptide but as a mixture of peptides of different lengths and amino acid derivatizations. Moreover, in hypergastrinaemia the peptide pattern changes. Consequently, diagnostic gastrin measurements require immunoassays that recognize the pathological plasma patterns, which are characterized by a predominance of the large peptides (gastrin-34 and gastrin-71) and less, if any, of the shorter main form of gastrin in normal tissue, gastrin-17. Alternatively, and in specific cases, "processing-independent assays" (PIA) for progastrin may be considered, since hypersecreting gastrin cells also release substantial amounts of biosynthetic precursors and processing intermediates. Recently, gastrin kits that do not take the pathological plasma patterns into account have been marketed and may miss the diagnosis. Therefore, proper diagnosis of gastrinomas and other hypergastrinaemic diseases requires insight into cellular gastrin synthesis and peripheral metabolism, and also into the design of useful immunoassays. This review discusses the art of measuring gastrin in plasma with adequate diagnostic specificity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19172694     DOI: 10.1080/00365510701771831

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  5 in total

Review 1.  Role of gastrin-peptides in Barrett's and colorectal carcinogenesis.

Authors:  Eduardo Chueca; Angel Lanas; Elena Piazuelo
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

2.  Effects of 12 weeks' treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study.

Authors:  K D Hove; C Brøns; K Færch; S S Lund; J S Petersen; A E Karlsen; P Rossing; J F Rehfeld; A Vaag
Journal:  Diabetologia       Date:  2012-09-26       Impact factor: 10.122

Review 3.  Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-12       Impact factor: 3.043

Review 4.  Gastrin and the Moderate Hypergastrinemias.

Authors:  Jens F Rehfeld
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 5.  Gastrin, Cholecystokinin, Signaling, and Biological Activities in Cellular Processes.

Authors:  Qiang Zeng; Lei Ou; Wei Wang; Dong-Yu Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-06       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.